Investment

US Congress
#Investment #Politics #United States #US Food and Drug Administration (FDA)

After the midterms, biopharma needs more than a policy forecast

A Democratic Congress will likely sharpen oversight of the FDA and drug pricing, but the most consequential choices for drug developers in 2027 will still be made in clinical trial protocols, financing plans and portfolio reviews.  Washington has had a leadership change, but the development equation has not.  The November… Read More

#Exclusive Content #Opinion

Financing or funding
#Arthritis #Financing #Investment #Rheumatology #Spinout

Anaheim Bio launches with €40 million Series A financing

Alesta Therapeutics spin-out Anaheim Bio has launched with an oversubscribed €40 million Series A financing.  The company was formed in 2026 from programmes spun out of Alesta Therapeutics and is backed by Alesta's former investors, including Droia Ventures, Frazier Life Sciences, RTW Investments, Novartis Venture Fund, RV Invest and Thuja… Read More

#Business & Investment #News #Start-up Zone

#AI / data analytics / healthtech / informatics #DDII #DDIIDigitalForum #Drug discovery #Investment #Technology

This week in Drug Discovery (26-30 October)

News round-up for 26-30 October 2026 by Megan Thomas, Multimedia Editor at DDW.  This week’s news roundup covers the upcoming Drug Discovery Innovators & Investors Conference in London, as well as four stories that showcase the far reaching impact of artificial intelligence (AI) in drug discovery. The… Read More

#News

#BioIndustry Association #Biotech #Financing #Investment #Venture funds

Q3 UK biotech VC heads for record year thanks to megadeals

UK biotech venture capital investment reached £270 million ($359 million), up 44% from £187 million ($248 million) in Q3 2025, according to new figures from the BioIndustry Association (BIA), as the sector heads for its best year since 2021.  The latest upswing comes as overall UK venture capital investment declines… Read More

#Business & Investment #Editor's Choice #News

UK Budget
#Association of the British Pharmaceutical Industry #Investment #Life sciences #UK #UK budget

UK Budget promises £70m for life sciences and lifts VAT on free medicines

In the 2026 Budget, Chancellor John Healey moved to settle a long-running VAT issue that had become a barrier to pharmaceutical companies providing free-of-charge medicines to NHS patients. Medicines supplied free of charge can provide a vital route to treatment for patients with serious conditions. Companies supply them through early… Read More

#Business & Investment #News #Trending News

#Antibody drug conjugate (ADC) #Biotech #Investment #Oncology #Women in STEM

Women in biopharma: Valerie Vanhooren, Ona Therapeutics 

In this series, DDW speaks to women in leading positions across biopharma about the work they’re doing and their experiences within the industry. Here, we speak to Valerie Vanhooren, Co-Founder & CEO, at Ona Therapeutics, about approaches in oncology, the remaining potential in the ADC field, and the advice Valerie… Read More

#Exclusive Content

#Biotechnology #Cancer research #Clinical trials #Drug development #Drug discovery #Investment #Technology #Tumours

This week in Drug Discovery (19-23 October)

News round-up for 19-23 October 2026 by Megan Thomas, Multimedia Editor at DDW.  In this week’s news roundup, drug discovery and biopharma companies continue to make progress across the drug development pipeline, with recent updates highlighting clinical trial milestones, emerging research and investment in new treatments. The… Read More

#News

#Biotechnology #Cancer research #DDII #DDIIDigitalForum #Drug discovery #Investment #Rare disease #Technology #Tumours

This week in Drug Discovery (12-16 October)

News round-up for 12-16 October 2026 by Megan Thomas, Multimedia Editor at DDW.  This week’s news roundup covers the upcoming Drug Discovery Innovators & Investors Conference in London, as well as new initiatives to accelerate rare disease drug development, promising preclinical data for Duchenne muscular dystrophy, clinical trial… Read More

#News

#Biotech #Drug discovery #Funding #Investment

3 key takes from Optimum’s Investor Conference

DDW Editor Reece Armstrong offers three key takeaways from Optimum's Annual Healthcare Investor Conference.  AI is still dominating the conversation AI was an obvious talking point throughout the conference, with its application in both investing and in drug discovery and development being major points of discussion. As someone who regularly… Read More

#Exclusive Content

AI roadmap
#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Drug discovery #Investment

AI investment by life science labs hits a four-year high, study finds

The results of a new study show AI/ML investment jumping after three flat years, with three quarters (76%) of respondents planning to increase spending on technology in the next two years, up from 60% in 2023, 62% in 2024, and 63% in 2025.  However, the leading barrier to digital transformation… Read More

#Business & Investment #Editor's Choice #News

#Biotechnology #Cancer research #DDII #DDIIDigitalForum #Drug discovery #Investment #Technology #Tumours

This week in Drug Discovery (5-9 October 2026) 

News round-up for 5-9 October, 2026 by Megan Thomas, Multimedia Editor at DDW.  This week’s news roundup covers the upcoming Drug Discovery Innovators & Investors Conference in London, as well as some promising updates in cancer research and immunotherapy, particularly the development of new treatments and how… Read More

#News

#Europe #Investment #Market reporting #Survey

European biopharma investment confidence increasing, c-suite survey reveals

Biopharma dealmaking confidence is strengthening, a new survey has revealed, but access to capital remains the defining challenge.  BIO-Europe’s Biopharma C-Suite Agenda Survey 2026 surveyed 81 senior biopharma executives, including 50 CEOs.  The survey results demonstrate that 75% expect partnering and M&A appetite to increase over the next 12 months,… Read More

#Business & Investment #Editor's Choice #News

#Biotechnology #Cancer research #DDII #DDIIDigitalForum #Drug discovery #Investment #Technology #Tumours

This week in Drug Discovery (28 September – 2 October 2026) 

News round-up for 28 September – 2 October 2026 by Megan Thomas, Content Team at DDW.  This week’s news roundup covers the upcoming the Drug Discovery Innovators & Investors Conference in London, as well as global updates on cancer research. The top stories:  In-person… Read More

#News

Europe
#Europe #Investment #Pharmaceutical industry

Pharma urges leaders to reverse Europe’s declining competitiveness

An open letter from the chairs of AstraZeneca, Boehringer Ingelheim, Chiesi Group, Ipsen, GSK, Novo, Novartis, Roche, and Sanofi has urged European governments to create conditions that attract investment in next-generation medicines.  They argue that Europe is losing ground to global competition, with over $600 billion in pharmaceutical investment announced… Read More

#Business & Investment #Editor's Choice #News

#Biotechnology #Cancer research #DDII #DDIIDigitalForum #Drug discovery #Investment #Technology #Tumours

This week in Drug Discovery (21-25 September 2026) 

News round-up for 21-25 September 2026 by Megan Thomas, Content Team at DDW.  This week’s news roundup covers the upcoming Drug Discovery Innovators & Investors Digital Forum and the Drug Discovery Innovators & Investors Conference in London, as well as the latest developments in drug discovery,… Read More

#News

#Biotechnology #Cancer research #DDII #DDIIDigitalForum #Drug discovery #Investment #Technology #Tumours

This week in Drug Discovery (14-18 September 2026) 

News round-up for 14-18 September 2026 by Megan Thomas, Content Team at DDW.  This week’s news roundup covers the upcoming Drug Discovery Innovators & Investors Digital Forum and the Drug Discovery Innovators & Investors Conference in London, changes to US scientific research grant screening, the UK’s… Read More

#News